Innovative Therapeutics in Oncology and Neuroscience
Paving the Way for Long-Term Growth
3
1
Substantial Topline Growth
Top-tier growth profile in biopharma
• Strong R&D and commercial execution.
>>7 new launches in next 3 years
> >15 commercial products by 2028
• Maximize potential with new
indications
2
Achieve Profitability
Target corporate profitability by end
of 2025
• Increase productivity and leverage
across the organization
• Continue R&D prioritization
• Cash resources¹ expected to take us
through profitability
Expand Global Pipeline
Grow portfolio through internal
discovery efforts and BD
Targeted approach in certain TAs and
modalities
• Continue to strengthen global &
China portfolio through BD
• At least one global IND per year
7
Abbreviations: Investigational New Drug (IND), therapeutic area (TA), business development (BD).
Note: (1) Cash and cash equivalents, short-term investments and restricted cash totaled $807.6 million as of December 31, 2023.
zaj-ǝbView entire presentation